Janney Montgomery Scott
CLSD

Janney Montgomery Scott’s Clearside Biomedical CLSD Stock Holding History

Janney Montgomery Scott’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,667
Closed -$104K – 2642
2023
Q1 		$104K Buy
+6,667
New +$129K ﹤0.01% 2366

Other funds holding CLSD

CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Janney Montgomery Scott's CLSD Position: Q2 2023 in Review

Janney Montgomery Scott sold out of Clearside Biomedical (CLSD) in Q2 2023, closing a stake of 6,667 shares — an estimated $104K sold.

Janney Montgomery Scott first reported a position in CLSD in Q1 2023 and held it in 1 quarter. The position peaked at $104K in Q1 2023. 54 funds tracked by Wall St. Rank hold CLSD as of Q2 2023.

  • Janney Montgomery Scott reported no remaining Clearside Biomedical position as of Q2 2023 after selling out during the quarter.
  • Janney Montgomery Scott sold 6,667 Clearside Biomedical shares in Q2 2023, an estimated $104K.
  • Janney Montgomery Scott first reported a position in Clearside Biomedical in Q1 2023 and held it in 1 quarter.
  • Janney Montgomery Scott's Clearside Biomedical position peaked at $104K in Q1 2023.
  • 54 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2023.

Based on Janney Montgomery Scott's 13F filing for Q2 2023, filed 26 Jul 2023.